Pyrrolopyrimidines as janus kinase inhibitors
US8993756B2 · kind B2 · utility
2Cited by
3References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 30, 2012 |
| Grant date | Mar 31, 2015 |
| Priority date | — |
| Expiry date | Nov 30, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The instant invention provides compounds of formula I which are JAK3 inhibitors. Specifically, the compounds of formula I are pyrrolo[2,3-d]pyrimidine derivative compounds. The instant invention also provides methods of treating JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer, by administering the pyrrolo[2,3-d]pyrimidine-derivative compounds of formula I.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.